SNDX Overview
Upcoming Projects (SNDX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (SNDX)
-
Examining the Phase 2 AGAVE-201 Trial Results for Axatilimab (Niktimvo) in Chronic Graft-Versus-Host Disease from Syndax (SNDX) and Incyte (INCY)
Tickers: SNDX, INCY
Executed On: Oct 21, 2024 at 03:30 PM EDT -
A look at the potential of menin inhibitors for patients with acute myeloid leukemias, specifically Syndax Pharmaceuticals' revumenib and how it compares to Kura's ziftomenib.
Ticker: SNDX
Executed On: Aug 19, 2024 at 10:00 AM EDT -
A Second Look: Discussing recent updates from EHA on menin inhibitors, including DSP-5336, JNJ-6617 in combo with Ven/Aza in r/r AML, and revumenib with the same combo but in newly diagnosed AML.
Tickers: KURA, JNJ, SNDX
Executed On: Jul 17, 2024 at 11:00 AM EDT -
Discussing recent updates from EHA on menin inhibitors, including DSP-5336, JNJ-6617 in combo with Ven/Aza in r/r AML, and revumenib with the same combo but in newly diagnosed AML.
Tickers: JNJ, SNDX, KURA
Executed On: Jun 25, 2024 at 09:30 AM EDT -
A Second View: Discussing the potential of Syndax Pharmaceuticals' axatilimab with chronic GVHD and the results from the AGAVE-201 trial presented at ASH.
Ticker: SNDX
Executed On: Dec 19, 2023 at 12:00 PM EST -
Discussing the potential of Syndax Pharmaceuticals' axatilimab with chronic GVHD and the results from the AGAVE-201 trial presented at ASH.
Ticker: SNDX
Executed On: Dec 14, 2023 at 02:15 PM EST -
Discussing the results of the AUGMENT-101 Phase 2 clinical trial of Syndax Pharma's Revumenib in patients with acute leukemia.
Ticker: SNDX
Executed On: Oct 11, 2023 at 03:00 PM EDT -
Digging into the recent data from ASH2022 on Syndax' revumenib (SNDX-5613) & Kura's ziftomenib in treating AML
Tickers: SNDX, KURA
Executed On: Dec 20, 2022 at 05:30 PM EST -
A discussion of ziftomenib (menin inhibitor) and outlook for KOMET-001 trial in r/r AML
Tickers: KURA, SNDX
Executed On: Oct 13, 2022 at 05:00 PM EDT -
Examining the potential of Syndax' Revumenib (SNDX-5613) in treating mNPM1 or mixed lineage leukemia rearranged (MLLr) relapsed/refractory (R/R) acute leukemias
Ticker: SNDX
Executed On: Aug 15, 2022 at 06:00 PM EDT
Upcoming & Overdue Catalysts (SNDX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (SNDX)
-
Syndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB's Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program
Tickers: SNDX, UCBB.F
Announcement Date: Jul 06, 2016
